Neoventa Medical
Sofia Blad is a highly experienced professional in the medical and clinical research field, currently serving as the Scientific and Clinical Director at Neoventa Medical since October 2024. Prior to this role, Sofia held various positions at Mediteq, including Manager and Senior Consultant for medical devices. As an entrepreneur, Sofia led the production and development of an innovative air purifier at Neoventor Medicinsk Innovation AB from 2012 to 2022. Other notable experiences include roles as a Clinical Specialist at Intertek Sweden and Global Strategic Evidence Manager at Mölnlycke Health Care, among several positions in clinical trials and project management at Vitrolife and Neoventa Medical. Sofia holds a Doctor of Philosophy in Physiology and a Master’s degree in Biology from the University of Gothenburg.
This person is not in any teams
This person is not in any offices
Neoventa Medical
Neoventa Medical AB is a Swedish medical device company founded in 1997 by Professor KG Rosén, Physiologist, Paediatrician & Neonatologist, trained at the University of Gothenburg, Sweden. Professor Rosén started Medical device developments, as a way to secure the use of his profound knowledge gained from experimental and clinical research inthe field of Fetal Monitoring.Neoventa provides innovative fetal monitoring solutions and services that improve obstetric care. Their solutions are designed to promote patient safety through enhanced decision support together with a structured workflow. Every day across the globe, health care professionals use their unique solutions to ensure a good start in life.Their core competence lies in using the STAN fetal monitor to perform evidence-based ST Analysis of the fetal ECG as an adjunct to CTG, “a second pair of eyes” during childbirth. They are also the provider of disposable fetal scalp electrodes for internal fetal monitoring under the brand Goldtrace. Another important area of business is a comprehensive education and training program, Neoventa Academy, which includes e-learning with certification.Numerous studies have shown that ST Analysis as an adjunct to CTG during labour reduces the number of babies born with risk of neurological damage, results in fewer operative deliveries, less need for fetal blood sampling and simultaneously being cost effective. The STAN fetal monitor has been used to deliver over one million children since its introduction in Europe. Over 15,000 patients have been enrolled in randomized trials and over 100,000 patients have been enrolled in observational studies.